DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Evaluation Of The Product Ciclo® 21 Pharmacodynamics (Levonorgestrel + Ethinyl Estradiol), Marketed By União Química Farmacêutica Nacional S / A, Compared To Nordette® Product To The Lab Wyeth Pharmaceutical Industries Ltd.

Information source: L.A.L Clinica Pesquisa e Desenvolvimento Ltda.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pregnancy Prevention; Control of Menstrual Irregularities

Intervention: Ciclo 21 (LNG + EE2); União Química Farmacêutcia Nacional S/A (Drug); Nordette (LNG + EE2); Laboratory Wyeth Pharmaceutical Ltda (Drug)

Phase: Phase 3

Status: Not yet recruiting

Sponsored by: L.A.L Clinica Pesquisa e Desenvolvimento Ltda.

Overall contact:
Alexandre Frederico, phsycian, Phone: 55 19 3871-6399, Email: alexandre@lalclinica.com.br

Summary

Assessment of the pharmacodynamic profile of the drug Ciclo 21 , marketed by Unio Qumica Farmacutica Nacional S / A, compared to the drug Nordette Laboratory Wyeth Pharmaceutical Ltda. Through the modulation of hormonal response (inhibition of the pituitary) evidenced by measurement serum LH and FSH for 28 days, as well as by the absence of follicle formation demonstrated by transvaginal ultrasound examinations

Clinical Details

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Primary outcome: The primary efficacy endpoint will be the changes in FSH and LH secretion induced by daily administration of the drug for 21 consecutive days during the 28 days of participation in the trial.

Secondary outcome: Safety of drugs: type, frequency and intensity of adverse events between groups during the 28 day trial. Exploratory investigation of the pharmacokinetics of the drug administered through the dosage of hormones in serum LNG and EE2 for 28 days.

Detailed description: secondary objective

- Evaluation of the safety aspects of medicines such as type, frequency and intensity of

adverse events between groups during the 28 day trial. exploratory objective

- Evaluation of the pharmacokinetics of the drug administered through the dosage of serum

hormone levonorgestrel and ethinyl estradiol for 28 days.

Eligibility

Minimum age: 18 Years. Maximum age: 35 Years. Gender(s): Female.

Criteria:

Inclusion Criteria: 1. Comply with all study procedures, sign, initial and date back, of their own free will, the IC; 2. Women aged between 18 and 35 years, regardless of race and class; 3. Make use of safe non-hormonal method of contraception such as tubal ligation, non-hormonal IUDs or condoms, or be hysterectomised or be vasectomized sexual partner; 4. Examination of Beta-HCG negative; 5. with regular menstrual cycles every 24 to 32 days, at least the last three months; 6. present normal Pap test (current or during the past 02 years); 7. Present or vaginal examination found that the changes do not interfere in the study; 8. present levels of FSH, LH, estradiol and TT for the normal menstrual cycle, as well as normal transvaginal sonographic reports. Exclusion Criteria: 1. Provide a contraindication to the use of steroids; 2. Use regular or prediction of drugs that interfere with the metabolism of the investigational products, such as antibiotics, anticonvulsants, anticoagulants and hypoglycemic drugs; 3. smokers or have stopped smoking less than 12 months; 4. Diabetic; 5. Toxic-dependent; 6. BMI <18 and> 25; 7. have made use of topical or systemic sex hormone for at least two months before the start of the study; 8. Background and personal or family history of thrombosis or bleeding disorders or vascular disorders or cardiovascular disease; 9. Laboratory tests, gynecological ultrasound or changed, the medical criteria; 10. Individuals with allergies or rheumatic diseases for which is indicated the use of cortico-steroid medication; 11. carry any endocrine changes, especially pituitary and gonadal and / or who are advised to use hormones; 12. with lesions or abnormalities suspected or confirmed in the gonads. 13. personal or family history of breast cancer or other hormone-dependent breast pathology; 14. with hypertension or diabetes mellitus (for drug interactions between the COC and hypoglycemic agents and antihypertensives); a) History of nausea with oral use of COCs; p) Any condition that may interfere with the discretion of the investigator in the study data as well as being the measurement of the study be deleterious to the patient.

Locations and Contacts

Alexandre Frederico, phsycian, Phone: 55 19 3871-6399, Email: alexandre@lalclinica.com.br

LAL Clínica Pesquisa e Desenvolvimento Ltda, Valinhos, São Paulo, Brazil; Not yet recruiting
Alexandre Frederico, phsycian, Phone: 55 19 3871-6399, Email: alexandre@lalclinica.com.br
Alexandre Frederico, phsician, Principal Investigator
Additional Information

Starting date: May 2013
Last updated: March 13, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017